Clinical Trials Directory

Trials / Completed

CompletedNCT04494282

The Economic Impact of the Pancreatography in the Endoscopic Treatment of Pancreatic Pseudocysts

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Pancreatic pseudocysts (PP) present as a complication that occurs in 5-15% of acute pancreatitis and 26-40% of chronic pancreatitis (1-3). To date the endoscopic drainage with endoscopic ultrasound (EUS) has replace the surgical treatment due to the similar success and complication rate but with a lower cost and short hospital stay (4-6). Regarding recurrence, it is important to know the anatomy of the main pancreatic duct (MPD). For this purpose, the endoscopic retrograde pancreatography (ERP) has been describe as a useful tool. In fact, many authors perform it before the endoscopic drainage while others wait several weeks after the drainage (7-9) with similar technical success (5,8). However, there are no studies that compare the technical difficulty and the total cost between these two approaches.

Detailed description

METHODS: Random control trial between two groups. Group 1 the ERP will be performed the same day of the endoscopic drainage of PP. Group 2 the ERP will be performed 6 weeks after the endoscopic drainage of PP. Each ERP will be performed by an expert in ERP in patients who fulfilled the Atlanta criteria for PP. The patients will be enrolled and informed consent will be explained and signed. In those patients who ERP fails, a second attempt will be performed 6 weeks after the endoscopic drainage of PP (Group 1) or a magnetic resonance cholangiopancreatography will be performed (Group 2).

Conditions

Interventions

TypeNameDescription
PROCEDUREEndoscopic retrograde pancreatographyEndoscopic cannulation of main pancreatic duct

Timeline

Start date
2015-08-01
Primary completion
2020-05-01
Completion
2020-05-01
First posted
2020-07-31
Last updated
2024-03-06

Source: ClinicalTrials.gov record NCT04494282. Inclusion in this directory is not an endorsement.